Xenon Pharmaceuticals Inc (XENE) saw an uptrend of 1442659% in the recent trading with $1040000.0 being its most recent. The current price level -30.96% lower than the highest price of $46.00 marked by the stock while trading over the past 52-weeks, whereas it is 18.77% higher than the lowest price of $26.74 the company dropped to over past 52-weeks. The latest news story on XENE appeared in (GlobeNewswire) under the title “Xenon Announces Appointment of Darren Cline as Chief Commercial Officer” on Jun-24-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.05 for the stock.
Xenon Pharmaceuticals Inc Earnings – What Happened With XENE
Coming around sales and income figures on XENE Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Xenon Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 76.59 million. XENE does have institutional investors; and they hold 97.49% of the stock.
As on 2024-06-30, FMR LLC was the top most holder in Xenon Pharmaceuticals Inc (NASDAQ:XENE) with an ownership of 6.77 million shares of the company or 8.7139 of the stake worth $263.89 million. The filing also reveals AVORO CAPITAL ADVISORS LLC as the second largest holder in the company with a control over 7.2957 of the outstanding shares. Its stake is worth $220.94 million for having 5.67 million shares in hand.
DRIEHAUS CAPITAL MANAGEMENT LLC also came holding a key position in the company during the recent quarter and it now holds 5.69 of the outstanding shares. With this there are now 285.0 institutions which have possession in XENE’s shares.
Key Metrics forXENE
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Xenon Pharmaceuticals Inc has a debt to equity ratio of 0.01.
Technical Analysis of Xenon Pharmaceuticals Inc (NASDAQ:XENE) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Xenon Pharmaceuticals Inc (XENE), we notice that the stock’s 20-day average volume is at 949,990 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 1,062,072 shares. And to end, XENE’s 100-day average volume is 837,594 shares with 100% of the long-term indicators pointing towards Sell for the stock.
